vs

Side-by-side financial comparison of ROCKY BRANDS, INC. (RCKY) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.

ROCKY BRANDS, INC. is the larger business by last-quarter revenue ($139.7M vs $70.6M, roughly 2.0× Viridian Therapeutics, Inc.\DE). ROCKY BRANDS, INC. runs the higher net margin — 4.7% vs -49.0%, a 53.7% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 9.1%). ROCKY BRANDS, INC. produced more free cash flow last quarter ($16.7M vs $-84.7M).

Rocky Brands, Inc., formerly known as Rocky Shoes & Boots, Inc., is a company which designs, develops, manufactures, and markets outdoor, work, western and military footwear, and other outdoor and work apparel and accessories. The company was founded in 1932 in Nelsonville, Ohio, and still maintains its corporate headquarters there.

Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.

RCKY vs VRDN — Head-to-Head

Bigger by revenue
RCKY
RCKY
2.0× larger
RCKY
$139.7M
$70.6M
VRDN
Growing faster (revenue YoY)
VRDN
VRDN
+81949.0% gap
VRDN
81958.1%
9.1%
RCKY
Higher net margin
RCKY
RCKY
53.7% more per $
RCKY
4.7%
-49.0%
VRDN
More free cash flow
RCKY
RCKY
$101.5M more FCF
RCKY
$16.7M
$-84.7M
VRDN

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
RCKY
RCKY
VRDN
VRDN
Revenue
$139.7M
$70.6M
Net Profit
$6.5M
$-34.6M
Gross Margin
41.3%
Operating Margin
6.9%
-56.7%
Net Margin
4.7%
-49.0%
Revenue YoY
9.1%
81958.1%
Net Profit YoY
35.7%
54.9%
EPS (diluted)
$0.86

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RCKY
RCKY
VRDN
VRDN
Q4 25
$139.7M
Q3 25
$122.5M
$70.6M
Q2 25
$105.6M
Q1 25
$114.1M
Q4 24
$128.1M
Q3 24
$114.6M
Q2 24
$98.3M
Q1 24
$112.9M
Net Profit
RCKY
RCKY
VRDN
VRDN
Q4 25
$6.5M
Q3 25
$7.2M
$-34.6M
Q2 25
$3.6M
Q1 25
$4.9M
Q4 24
$4.8M
Q3 24
$5.3M
Q2 24
$-1.2M
Q1 24
$2.5M
Gross Margin
RCKY
RCKY
VRDN
VRDN
Q4 25
41.3%
Q3 25
40.2%
Q2 25
41.0%
Q1 25
41.2%
Q4 24
41.5%
Q3 24
38.1%
Q2 24
38.7%
Q1 24
39.1%
Operating Margin
RCKY
RCKY
VRDN
VRDN
Q4 25
6.9%
Q3 25
9.6%
-56.7%
Q2 25
6.8%
Q1 25
7.6%
Q4 24
6.6%
Q3 24
8.8%
Q2 24
4.6%
Q1 24
7.1%
Net Margin
RCKY
RCKY
VRDN
VRDN
Q4 25
4.7%
Q3 25
5.9%
-49.0%
Q2 25
3.4%
Q1 25
4.3%
Q4 24
3.7%
Q3 24
4.6%
Q2 24
-1.3%
Q1 24
2.3%
EPS (diluted)
RCKY
RCKY
VRDN
VRDN
Q4 25
$0.86
Q3 25
$0.96
Q2 25
$0.48
Q1 25
$0.66
Q4 24
$0.65
Q3 24
$0.70
Q2 24
$-0.17
Q1 24
$0.34

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RCKY
RCKY
VRDN
VRDN
Cash + ST InvestmentsLiquidity on hand
$2.9M
$490.9M
Total DebtLower is stronger
$122.6M
Stockholders' EquityBook value
$252.1M
$503.0M
Total Assets
$477.5M
$577.1M
Debt / EquityLower = less leverage
0.49×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RCKY
RCKY
VRDN
VRDN
Q4 25
$2.9M
Q3 25
$3.3M
$490.9M
Q2 25
$2.8M
Q1 25
$2.6M
Q4 24
$3.7M
Q3 24
$3.7M
Q2 24
$4.1M
Q1 24
$3.1M
Total Debt
RCKY
RCKY
VRDN
VRDN
Q4 25
$122.6M
Q3 25
$139.0M
Q2 25
$132.5M
Q1 25
$128.6M
Q4 24
$128.7M
Q3 24
$150.3M
Q2 24
$152.4M
Q1 24
$156.0M
Stockholders' Equity
RCKY
RCKY
VRDN
VRDN
Q4 25
$252.1M
Q3 25
$246.1M
$503.0M
Q2 25
$239.1M
Q1 25
$236.2M
Q4 24
$232.2M
Q3 24
$228.3M
Q2 24
$223.8M
Q1 24
$225.3M
Total Assets
RCKY
RCKY
VRDN
VRDN
Q4 25
$477.5M
Q3 25
$494.0M
$577.1M
Q2 25
$471.0M
Q1 25
$468.2M
Q4 24
$457.3M
Q3 24
$475.0M
Q2 24
$467.9M
Q1 24
$466.5M
Debt / Equity
RCKY
RCKY
VRDN
VRDN
Q4 25
0.49×
Q3 25
0.57×
Q2 25
0.55×
Q1 25
0.54×
Q4 24
0.55×
Q3 24
0.66×
Q2 24
0.68×
Q1 24
0.69×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RCKY
RCKY
VRDN
VRDN
Operating Cash FlowLast quarter
$17.6M
$-84.6M
Free Cash FlowOCF − Capex
$16.7M
$-84.7M
FCF MarginFCF / Revenue
12.0%
-120.1%
Capex IntensityCapex / Revenue
0.6%
0.2%
Cash ConversionOCF / Net Profit
2.70×
TTM Free Cash FlowTrailing 4 quarters
$9.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RCKY
RCKY
VRDN
VRDN
Q4 25
$17.6M
Q3 25
$-3.3M
$-84.6M
Q2 25
$812.0K
Q1 25
$1.2M
Q4 24
$24.4M
Q3 24
$4.5M
Q2 24
$6.5M
Q1 24
$17.4M
Free Cash Flow
RCKY
RCKY
VRDN
VRDN
Q4 25
$16.7M
Q3 25
$-5.2M
$-84.7M
Q2 25
$-2.4M
Q1 25
$529.0K
Q4 24
$22.9M
Q3 24
$3.5M
Q2 24
$4.6M
Q1 24
$17.1M
FCF Margin
RCKY
RCKY
VRDN
VRDN
Q4 25
12.0%
Q3 25
-4.2%
-120.1%
Q2 25
-2.2%
Q1 25
0.5%
Q4 24
17.9%
Q3 24
3.0%
Q2 24
4.7%
Q1 24
15.2%
Capex Intensity
RCKY
RCKY
VRDN
VRDN
Q4 25
0.6%
Q3 25
1.5%
0.2%
Q2 25
3.0%
Q1 25
0.6%
Q4 24
1.2%
Q3 24
0.9%
Q2 24
1.9%
Q1 24
0.2%
Cash Conversion
RCKY
RCKY
VRDN
VRDN
Q4 25
2.70×
Q3 25
-0.46×
Q2 25
0.23×
Q1 25
0.25×
Q4 24
5.08×
Q3 24
0.85×
Q2 24
Q1 24
6.82×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RCKY
RCKY

Wholesale$79.6M57%
Retail1$57.0M41%
Contract Manufacturing$3.2M2%

VRDN
VRDN

Segment breakdown not available.

Related Comparisons